Pfizer Says Its Vaccine Is Highly Effective in 5- to 11-Year-Olds

2 years ago 178
A pharmacist collecting Pfizer-BioNTech coronavirus vaccine syringes successful  San Rafael, Calif., successful  September.
Credit...Jim Wilson/The New York Times
  • Oct. 22, 2021Updated 9:49 a.m. ET

Pfizer reported information connected Friday showing that its vaccine had a 90.7 percent efficacy complaint successful preventing symptomatic Covid-19 successful a objective proceedings of children ages 5 to 11.

The institution submitted the information to the Food and Drug Administration, which was expected to merchandise its ain investigation of the information aboriginal successful the day.

Children successful the proceedings received a dose of 10 micrograms, smaller than the 30-microgram dose fixed to adults. The institution said that the dosage was safe, and that proceedings participants had seen lone mild broadside effects.

Of 2,268 children successful the trial, doubly arsenic galore were fixed the vaccine arsenic received a placebo. Sixteen children who received the placebo got Covid-19, compared with 3 who received the vaccine, a effect that translates to much than 90 percent efficacy.

The institution released the information earlier a gathering adjacent week astatine which adept advisers to the F.D.A. volition determine whether to urge that the bureau authorize the vaccine for children successful this property group. Federal regulators person already made the vaccine disposable for those 12 and older.

If the F.D.A. authorizes the vaccine for ages 5 to 11 — a determination that could assistance support much than 28 cardinal radical successful the United States — the Centers for Disease Control and Prevention volition past marque recommendations to the bureau adjacent period connected however the shots should beryllium administered.

According to data collated by The New York Times, 66 percent of the U.S. colonisation has received astatine slightest 1 dose of a Covid vaccine, portion 57 percent are afloat vaccinated.

Read Entire Article